In summary, these results suggest that DLBCL cells rely on Bcl-2, Mcl-1 or Bcl-XL for resistance to apoptosis, and these vulnerabilities can be readily identified and exploited for treatment purposes. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.